Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance

Clear cell renal cell carcinoma (ccRCC) is characterized by high histone deacetylase (HDAC) activity triggering both cell motility and the development of metastasis. Therefore, there is an unmet need to establish innovative strategies to advance the use of HDAC inhibitors (HDACIs). We selected a set...

Full description

Bibliographic Details
Main Authors: Magdalena Rausch, Andrea Weiss, Marloes Zoetemelk, Sander R. Piersma, Connie R. Jimenez, Judy R. van Beijnum, Patrycja Nowak-Sliwinska
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
drug–drug interaction
HDAC inhibitor
multi-drug combination
renal cell carcinoma
therapeutically guided multidrug optimization (TGMO)
tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/2072-6694/12/11/3172

Internet

https://www.mdpi.com/2072-6694/12/11/3172

Similar Items